)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Celcuity (CELC) investor relations material
Celcuity Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary14 Aug, 2025
Executive summary
Achieved statistically significant and clinically meaningful improvements in both primary endpoints for the PIK3CA wild-type cohort in the Phase 3 VIKTORIA-1/VICTORIA-one trial for HR+/HER2- advanced breast cancer, with gedatolisib reducing risk of progression or death by 76% and significant PFS improvements.
Enrollment ongoing for PIK3CA mutant cohort and additional pivotal trials; topline data for mutant cohort expected in Q4 2025.
First patient dosed in Phase 3 VIKTORIA-2/VICTORIA-two trial for first-line HR+/HER2- ABC; favorable early results in prostate and breast cancer studies.
Issued new patent for gedatolisib dosing regimen, extending exclusivity to 2042.
Raised over $286M through equity, convertible notes, and warrant offerings to fund operations and clinical development.
Financial highlights
Q2 2025 net loss was $45.3M ($1.04/share), up from $23.7M ($0.62/share) in Q2 2024; non-GAAP adjusted net loss was $40.5M ($0.93/share) vs. $22.2M ($0.58/share) year-over-year.
R&D expenses rose to $40.2M from $22.5M, mainly due to increased personnel, trial costs, and a $5M milestone payment to Pfizer.
General and administrative expenses increased to $3.8M, reflecting higher personnel and professional fees.
Ended Q2 with $168.4M in cash and equivalents; pro forma including Q3 financing, cash position is $455M.
Interest expense for the quarter was $3.2M, up 42% year-over-year due to increased debt.
Outlook and guidance
NDA submission for gedatolisib planned for Q4 2025; topline data for PIK3CA mutant cohort also expected in Q4 2025.
Cash, investments, and available borrowings expected to fund operations and commercialization through 2027.
Anticipated increases in R&D and G&A expenses as clinical programs expand and commercialization preparations accelerate.
What PFS delta is clinically meaningful for PIK3CA mutant?
How does Celcuity plan to scale infrastructure for launch?
What are the ramifications of doublet/triplet optionality?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Celcuity earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Celcuity Inc. is a biotechnology company focused on developing diagnostic tests to improve the treatment of cancer. The company specializes in functional cellular analysis, using its proprietary CELsignia platform to identify molecular and cellular changes in a patient’s cancer cells. This technology helps detect new cancer subtypes and matches patients with targeted therapies that are most likely to be effective. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage